InsiderPulse
Dashboard

NBIX

Neurocrine Biosciences, Inc.

Health CareRussell 2000

Neurocrine Biosciences, Inc. insider trading

Neurocrine Biosciences, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in San Diego, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent NBIX insider transactions

9 insiders traded NBIX on the open market between Jun 01, 2026 and Sep 14, 2026 — 24 sales worth $19.8M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$19.8M

24 of 24 on a 10b5-1 plan

Net
−$19.8M
Insiders
9

Open-market purchases (code P) and sales (code S) from Neurocrine Biosciences, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every NBIX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

NBIX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 16 insiders traded NBIX on the open market: 0 purchases and 104 sales worth $152.5M, 102 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 35 sales ($95.6M), by 14 insiders.

QuarterBoughtSold
Q2 2026—−$57M21 sales · all on a plan
Q1 2026—−$4.8M2 sales · all on a plan
Q4 2025—−$9.8M8 sales · 7 on a plan
Q3 2025—−$24M4 sales · all on a plan
Q2 2025—−$4.5M2 sales · all on a plan
Q1 2025—−$38.7M45 sales · all on a plan
Q4 2024—−$626.4K4 sales · all on a plan
Q3 2024—−$13.2M18 sales · 17 on a plan
Largest sale
−$37.8M of NBIX by Gorman Kevin Charles (Director) on May 19, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Lippoldt Darin10b5-1

    Chief Legal Officer

    −$1.4M

    Jun 29, 2026

    8,110 sh · $170.03

  • Lippoldt Darin10b5-1

    Chief Legal Officer

    −$288.7K

    Jun 29, 2026

    1,690 sh · $170.81

  • Lippoldt Darin10b5-1

    Chief Legal Officer

    −$33.9K

    Jun 26, 2026

    200 sh · $169.57

  • Sherwin Stephen A10b5-1

    Director

    −$1.3M

    Jun 05, 2026

    7,883 sh · $163.81

  • Sherwin Stephen A10b5-1

    Director

    −$1.1M

    Jun 05, 2026

    6,896 sh · $165.79

  • Sherwin Stephen A10b5-1

    Director

    −$970.9K

    Jun 05, 2026

    5,829 sh · $166.56

  • Sherwin Stephen A10b5-1

    Director

    −$419.2K

    Jun 05, 2026

    2,549 sh · $164.44

  • Sherwin Stephen A10b5-1

    Director

    −$308.4K

    Jun 05, 2026

    1,843 sh · $167.31

  • Norwalk Leslie V10b5-1

    Director

    −$210.1K

    Jun 04, 2026

    1,250 sh · $168.06

  • Cooke Julie10b5-1

    Chief Human Resources Officer

    −$2.2M

    Jun 02, 2026

    14,214 sh · $154.83

  • Cooke Julie10b5-1

    Chief Human Resources Officer

    −$1.5M

    Jun 02, 2026

    9,521 sh · $157.62

  • Cooke Julie10b5-1

    Chief Human Resources Officer

    −$849.7K

    Jun 02, 2026

    5,466 sh · $155.46

  • Cooke Julie10b5-1

    Chief Human Resources Officer

    −$660.9K

    Jun 02, 2026

    4,216 sh · $156.77

  • Cooke Julie10b5-1

    Chief Human Resources Officer

    −$558.2K

    Jun 02, 2026

    3,520 sh · $158.59

  • Onyia Jude10b5-1

    Chief Scientific Officer

    −$1.8M

    Jun 01, 2026

    11,000 sh · $160.25

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Neurocrine Biosciences, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
San Diego, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0000914475

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought NBIX

What the stock actually did in the 90 days following each open-market purchase

Don't check NBIX — let it ping you

Get told the moment an insider moves on NBIX

Pro watches Neurocrine Biosciences, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add NBIX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track NBIX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read NBIX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

SRPTALNYBMRNINCYJAZZHALOEXASNTRACRSPNTLABEAMRXRX
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are NBIX insiders buying or selling?
Between Jun 01, 2026 and Sep 14, 2026, 9 Neurocrine Biosciences, Inc. insiders made no open-market purchases and 24 sales worth $19.8M, a net sale of $19.8M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much NBIX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 16 Neurocrine Biosciences, Inc. insiders made no open-market purchases and 104 sales worth $152.5M. 102 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 35 sales ($95.6M). The largest sale was Gorman Kevin Charles selling $37.8M on May 19, 2026.
What was the largest recent NBIX insider trade?
Cooke Julie (Chief Human Resources Officer) sold $2.2M of NBIX stock on Jun 02, 2026 at about $154.83 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy NBIX shares?
No open-market purchase by a Neurocrine Biosciences, Inc. insider appears in the filings from Jun 01, 2026 to Sep 14, 2026 — every recorded open-market transaction in that period was a sale.
Where does NBIX insider trading data come from?
From the Form 4 filings Neurocrine Biosciences, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.